Greenhaven Road Capital Main Fund Q4 2025 Shareholder Letter

Why It Matters

The fund’s positioning highlights undervalued assets poised for earnings acceleration, offering investors a potential rebound after a challenging year. Understanding these catalysts helps stakeholders gauge where future outperformance may originate.

Key Takeaways

• Lifecore aims to boost capacity utilization to 100% by 2026.
• Vistry shifting to asset‑light partnership model, targeting valuation re‑rating.
• Burford’s Argentina YPF judgment likely upheld, reducing downside risk.
• PAR wins Papa Johns contract, adding $14 M ARR, de‑risking pipeline.
• Hagerty’s State Farm partnership could add 1 M policies, boosting earnings.

Pulse Analysis

The shareholder letter underscores a classic value‑investment paradox: strong underlying business growth can coexist with lagging share prices. Lifecore Biomedical, operating at a fraction of its capacity, is leveraging new multinational contracts and a favorable regulatory environment to drive utilization toward full scale. If the company reaches 100% capacity, its operating leverage could push EBITDA margins above 30%, turning a $500 million enterprise value into a multi‑hundred‑million profit engine. Vistry’s pivot from traditional homebuilding to government‑backed mixed‑income projects mirrors a broader industry shift toward asset‑light models, freeing capital for share repurchases and potentially unlocking a 5‑plus‑times book‑value premium.

Conversely, the “Other Shoe Not Dropping” theme spotlights firms where market sentiment has over‑penalized risk. Burford’s litigation‑finance business carries a high‑return profile, and the pending YPF judgment against Argentina is statistically likely to be upheld, contradicting the 30% price decline. PAR’s recent win with Papa Johns adds $14 million of ARR and validates its AI‑enhanced platform, while its longstanding relationships with McDonald’s and Burger King keep a pipeline of large‑scale contracts alive. Cellebrite’s niche in high‑security forensics remains insulated from generic AI‑driven software disruption, and KKR’s record‑setting fundraising demonstrates resilience in the alternative‑asset space despite headline‑driven concerns.

Hagerty exemplifies a success story within the portfolio, with a 36% stock rally fueled by the onboarding of State Farm policies and explosive growth in its automotive marketplace. The addition of over a million policies will materially expand the revenue base, while operating leverage is set to lift EBIT margins toward 20%+. For investors, the letter signals that the fund’s underperformance is largely a timing issue; the identified catalysts across biotech manufacturing, real‑estate partnerships, litigation finance, SaaS, and insurance suggest a multi‑sector rebound that could translate into significant upside for shareholders.